Results 131 to 140 of about 265,018 (314)
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq +19 more
core +1 more source
Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance
Advanced Science, EarlyView.Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer +9 more
wiley +1 more source
Advanced Intelligent Discovery, EarlyView.scTIGER2.0 is a deep‐learning framework that infers gene regulatory networks from single‐cell RNA sequencing data. By integrating correlation, pseudotime ordering, deep learning and bootstrap‐based significance testing, it reduces false positives and reveals directional gene interactions.
Nishi Gupta +3 more
wiley +1 more source
Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice
American Journal of Hematology, EarlyView.ABSTRACT Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Despite advances in supportive and targeted therapies, disease‐modifying interventions remain limited.
Shahla Vilcassim +13 more
wiley +1 more source
Proteomic Identification of the MYST Domain Histone Acetyltransferase TIP60 as a Coactivator of the Myeloid Transcription Factor C/EBPα [PDF]
, 2007 The transcription factor C/EBPα is a key player in granulopoiesis and leukemogenesis. In the present study, we sought to identify C/EBPα interacting proteins.
Bararia, Deepak
core
Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study
American Journal of Hematology, EarlyView.ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim +11 more
wiley +1 more source
Journal of the National Comprehensive Cancer Network, 2011 Margaret R, O'Donnell +19 more
openaire +2 more sources
American Journal of Hematology, EarlyView.ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima +48 more
wiley +1 more source
Therapy of Acute Myeloid Leukemia
Cancer Control, 2001 The Eastern Cooperative Oncology Group (ECOG) has recently reviewed the outcome for more than 1,400 patients with previously untreated AML entered on five successive clinical trials.5,6 Each trial included daunorubicin and cytarabine for induction.
openaire +2 more sources
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management
American Journal of Hematology, EarlyView.ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley +1 more source